Cochlear Limited (ASX: COH) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Cochlear Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Cochlear Limited (ASX: COH)
Latest News
Share Market News
Blue-chip growth shares: REA Group Limited names new CFO
Growth Shares
Why I would buy A2 Milk Company and these ASX growth shares this month
Share Market News
Has the Cochlear share price bottomed out?
Growth Shares
Why I would buy Cochlear, CSL, and ResMed shares in April
Share Market News
Why this fund manager is underweight CSL shares
Growth Shares
Where to invest $5,000 in ASX 200 shares in April
Growth Shares
Is the CSL share price a buy?
⏸️ ASX Shares
Are these blue chip ASX 200 shares in the buy zone?
Share Market News
5 things to watch on the ASX 200 on Monday
Share Gainers
Is the Nanonsonics share price a buy?
Share Fallers
Cochlear share price slides lower on broker downgrade
Growth Shares
Why Cochlear and these top ASX shares could be great buy and hold investments
Frequently Asked Questions
-
Yes, Cochlear Ltd has historically paid two fully franked dividends a year.
-
Cochlear Ltd generally pays its dividends in April and October.
-
Cochlear Ltd listed on the ASX on 4 December 1995.
COH ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Cochlear Limited
Cochlear Ltd (ASX: COH) is the world's leading cochlear implant device manufacturer with around half of global market share.
The company was founded in Australia in 1983 to commercialise implants pioneered by Melbourne researcher Dr Graeme Clark, but later became a separate entity.
Developed markets contribute the bulk of Cochlear's group revenue with cochlear implants the standard of care for children with severe to profound hearing loss. The company is also catering for a growing cohort of seniors when standard hearing aid technology loses its effectiveness.
Cochlear's main products include cochlear implants, bone-anchored hearing devices, and associated sound processors. The vast majority of Cochlear's revenue is derived from overseas, with the US and Europe by far the company's two largest markets.
